How We’re Using Precision Medicine to Transform Resident Safety
Beyond “Trial and Error”
How We’re Using Precision Medicine to Transform Resident Safety
In long-term care, we’re all familiar with the scenario. A new medication is started, and a resident—who was stable—falls. Another resident is put on a standard dose of a blood thinner, only to have it fail, leading to a catastrophic event. A third complains of debilitating muscle pain from a statin and is labeled “non-compliant.”
For decades, the clinical response has been a frustrating cycle of “trial and error.” But what if it’s not just bad luck? What if these outcomes are predictable?
At MedElite, we believe the “one-size-fits-all” model of prescribing is no longer acceptable for the complex, vulnerable population we serve. This belief is at the heart of our clinical partnerships, including our work with leading organizations like Priority Healthcare Group (PHG). We were privileged to discuss this very topic at a recent PHG event honoring their Directors of Nursing—the clinical leaders who manage this challenge daily.
The topic? Pharmacogenomics (PGx). And it’s changing everything.
The $7.6 Billion Problem
Adverse Drug Events (ADEs) are one of the greatest threats to resident safety in nursing facilities. It’s a staggering financial problem, costing an estimated $7.6 billion annually. But more importantly, it’s a human one.
These ADEs manifest as falls , avoidable rehospitalizations , and a cascade of polypharmacy that makes a nurse’s med-pass exponentially more complex and dangerous. The central challenge is that two people can take the exact same dose of the exact same drug and have wildly different outcomes.
Pharmacogenomics explains why.
What is Pharmacogenomics (PGx)?
In short, PGx is the study of how an individual’s unique genetic makeup influences their response to drugs. It combines pharmacology with genomics to help personalize drug therapy, optimize effectiveness, and minimize risk.
This is a one-time test that provides a lifelong “instruction manual” for a patient’s body.
Most of this comes down to metabolism. Our bodies use a family of enzymes—primarily the “CYP” enzymes—to break down and activate medications. But based on our genes, we all metabolize differently:
- Poor Metabolizers: Break down a drug very slowly, leading to a toxic buildup and severe side effects.
- Intermediate Metabolizers: Have reduced enzyme activity.
- Normal Metabolizers: Have the “expected” enzyme activity.
- Ultrarapid Metabolizers: Break down a drug so quickly that it’s eliminated before it can work, leading to therapeutic failure.
Without this genetic information, we are, quite literally, prescribing blind.
PGx in Practice: Three Cases Where Genetics Changed Everything
This isn’t theory; it’s practical, actionable clinical science.
Case 1: The “Ineffective” Blood Thinner Many of the most common antiplatelet drugs, like Clopidogrel (Plavix), are “prodrugs.” This means they are inert when swallowed and must be activated by the CYP2C19 enzyme to work.
- The Problem: A patient is identified through a PGx test as a “poor metabolizer” of CYP2C19.
- The Clinical Risk: Their body cannot activate the drug. They are at an “increased risk of therapeutic failure”, meaning they are unprotected from a future heart attack or stroke, despite “taking their meds” perfectly.
- The PGx Solution: The provider is alerted and can instead prescribe an alternative like Ticagrelor (Brilinta), which is not activated by the same genetic pathway. This simple switch can, quite literally, save a life.
Case 2: The “Non-Compliant” Statin Patient A provider prescribes a statin to a resident to manage high cholesterol. The resident soon reports severe, debilitating muscle pain—a known side effect called SAMS (Statin-Associated Musculoskeletal Symptoms).
- The Problem: A gene called SLCO1B1 provides instructions for a protein that transports statins into the liver to be cleared. A PGx test reveals this patient has “decreased function” of this gene.
- The Clinical Risk: The statin isn’t being transported into the liver. Instead, it builds up in the bloodstream to toxic levels, causing the muscle pain.
- The PGx Solution: This resident isn’t “non-compliant”; they are genetically intolerant. The PGx test provides the data to justify selecting a different statin that is less dependent on this pathway, ensuring they can be protected from cardiovascular disease without suffering.
Case 3: The Fall That Was Prevented This is perhaps the most powerful example. A resident was identified as a “High Fall Risk” and had fallen four times in just three months (3 times in Dec/Jan, 1 in Feb). The patient was taking Imipramine, a tricyclic antidepressant.
- The Problem: A PGx test revealed the patient was a “Rapid Metabolizer” for the gene (CYP2C19) that processes this drug.
- The Clinical Risk: The patient’s body was likely clearing the drug too quickly, leading to “therapy failure or increased side effects” —a perfect storm for instability and falls.
- The PGx-Guided Intervention: Our pharmacist recommended discontinuing the Imipramine and switching to an alternative (Sertraline/Zoloft) that would be more effective for their genetic profile. The prescriber agreed.
- The Outcome: “Patient has not fallen since med change”.
A Partnership for Better Outcomes
This is the standard of care we are building with our partners at Priority Healthcare Group. By celebrating their DONs, we are celebrating a shared commitment to clinical excellence.
This data isn’t just a report; it’s a tool for change. It empowers DONs and providers to have data-driven conversations about deprescribing. It provides the objective evidence needed to support psychotropic stewardship. And, as the case study shows, it directly prevents harm.
The era of “trial and error” is over. Precision medicine is here, and by integrating it directly into the long-term care setting, we are proud to be working with our partners to deliver safer, more effective, and truly personalized care.
